Dr. Brian T. Dietrich

Hematology Oncology
300 Pasteur Dr, Grant S101, 
Stanford, CA 
300 Pasteur Dr, Grant S101, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Dietrich is a Hematologist Oncology provider in Stanford, California. His top areas of expertise are Urothelial Cancer and Bladder Cancer.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

300 Pasteur Dr, Grant S101, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Procedure, Biological, Drug, Other, Radiation
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Durvalumab, Gemcitabine, Methotrexate, Vinblastine, Fluorouracil, Mitomycin C
Study Phase: Phase 2
View 4 Less Clinical Trials

5 Total Publications

Molecular profiling of a primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid.
Molecular profiling of a primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid.
Journal: Journal of cutaneous pathology
Published: February 11, 2020
Similar Doctors
Wen-kai Weng
Expertise in
38
conditions
Dr. Wen-kai Weng
Hematology Oncology | Oncology
Expertise in
38
conditions
Dr. Wen-kai Weng
Hematology Oncology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wen-kai Weng is a Hematologist Oncology specialist and an Oncologist in Stanford, California. Dr. Weng is highly rated in 38 conditions, according to our data. His top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Graft Versus Host Disease (GvHD), Cutaneous T-Cell Lymphoma (CTCL), and Bone Marrow Transplant.

Expertise in
19
conditions
Dr. Terence W. Friedlander
Hematology Oncology | Hematology | Oncology
Expertise in
19
conditions
Dr. Terence W. Friedlander
Hematology Oncology | Hematology | Oncology

Ucsf Medical Group Business Services

3100 San Pablo Ave, 
Berkeley, CA 
 (29.5 miles away)
510-985-5020
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Terence Friedlander is a Hematologist Oncology specialist and a Hematologist in Berkeley, California. Dr. Friedlander is highly rated in 19 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Urothelial Cancer, Bladder Cancer, and Prostatectomy.

Expertise in
13
conditions
Dr. Ajai V. Chari
Hematology Oncology | Hematology | Oncology
Expertise in
13
conditions
Dr. Ajai V. Chari
Hematology Oncology | Hematology | Oncology

Ucsf Medical Group Business Services

3100 San Pablo Ave, 
Berkeley, CA 
 (29.5 miles away)
510-985-5020
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ajai Chari is a Hematologist Oncology specialist and a Hematologist in Berkeley, California. Dr. Chari is highly rated in 13 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dietrich's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile